Charis E. Teh

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jianan Gong et al. · Cancer Discovery · 2018 · 426 citations · Full text

Life Sciences, Genetics, Hematology +10

CIS is a potent checkpoint in NK cell–mediated tumor immunity

Rebecca B. Delconte, Tatiana B. Kolesnik, Laura F. Dagley et al. · Nature Immunology · 2016 · 387 citations

Life Sciences, Immunology, Oncology +13

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

Rishu Agarwal, Yih-Chih Chan, Constantine S. Tam et al. · Nature Medicine · 2018 · 204 citations · Full text

Medicine, Molecular Biology, Oncology +17

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

Sheau Wen Lok, James R. Whittle, François Vaillant et al. · Cancer Discovery · 2019 · 145 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

ATP11C is critical for the internalization of phosphatidylserine and differentiation of B lymphocytes

Mehmet Yabas, Charis E. Teh, Sandra Frankenreiter et al. · Nature Immunology · 2011 · 133 citations

Life Sciences, Cell Biology, Molecular Biology +7